144 related articles for article (PubMed ID: 34704813)
21. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
[TBL] [Abstract][Full Text] [Related]
22. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Dal Maso A; Lorenzi M; Roca E; Pilotto S; Macerelli M; Polo V; Cecere FL; Del Conte A; Nardo G; Buoro V; Scattolin D; Monteverdi S; Urso L; Zulato E; Frega S; Bonanno L; Indraccolo S; Calabrese F; Conte P; Pasello G
Clin Lung Cancer; 2020 Jan; 21(1):1-14.e3. PubMed ID: 31601525
[TBL] [Abstract][Full Text] [Related]
23. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
24. Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
Kogo M; Fujimoto D; Hosoya K; Nagata K; Nakagawa A; Tachikawa R; Yamashita D; Kitamura Y; Imai Y; Tomii K
BMC Cancer; 2020 Feb; 20(1):104. PubMed ID: 32028905
[TBL] [Abstract][Full Text] [Related]
25. [Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].
Cao Z; Wang J; Qin N; Li K; Lv J; Wang J; Yang X; Li X; Zhang H; Zhang Q; Long H; Shu C; Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):84-90. PubMed ID: 32093452
[TBL] [Abstract][Full Text] [Related]
26. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.
Ito M; Miyata Y; Hirano S; Irisuna F; Kushitani K; Kai Y; Kishi N; Tsutani Y; Takeshima Y; Okada M
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1419-1428. PubMed ID: 34218331
[TBL] [Abstract][Full Text] [Related]
28. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
29. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
Vanderlaan PA; Yamaguchi N; Folch E; Boucher DH; Kent MS; Gangadharan SP; Majid A; Goldstein MA; Huberman MS; Kocher ON; Costa DB
Lung Cancer; 2014 Apr; 84(1):39-44. PubMed ID: 24513263
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of the cobas EGFR Mutation Assay in Non-small-cell Lung Cancer Compared With Three Laboratory-developed Tests.
Nakamura H; Koizumi H; Sakai H; Kimura H; Miyazawa T; Marushima H; Saji H; Takagi M
Clin Lung Cancer; 2018 Mar; 19(2):170-174. PubMed ID: 29150249
[TBL] [Abstract][Full Text] [Related]
31. A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
Jensen SG; Epistolio S; Madsen CL; Kyneb MH; Riva A; Paganotti A; Barizzi J; Petersen RK; Børgesen M; Molinari F; Boldorini R; Lorenzen J; Sørensen E; Christensen UB; Høgdall E; Frattini M
PLoS One; 2021; 16(6):e0253687. PubMed ID: 34166445
[TBL] [Abstract][Full Text] [Related]
32. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy.
Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM
Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713
[TBL] [Abstract][Full Text] [Related]
33. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
[TBL] [Abstract][Full Text] [Related]
34. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
35. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
36. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
[TBL] [Abstract][Full Text] [Related]
37. EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer.
Satoh Y; Matsuo Y; Kuba T; Yamashita K; Sawano M; Tozaka S; Yamazaki H; Sonoda D; Mikubo M; Naito M; Matsui Y; Shiomi K; Yoshida T; Murakumo Y
Virchows Arch; 2020 May; 476(5):753-762. PubMed ID: 31823000
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.
Oxnard GR; Paweletz CP; Kuang Y; Mach SL; O'Connell A; Messineo MM; Luke JJ; Butaney M; Kirschmeier P; Jackman DM; Jänne PA
Clin Cancer Res; 2014 Mar; 20(6):1698-1705. PubMed ID: 24429876
[TBL] [Abstract][Full Text] [Related]
39. Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.
Kitazono S; Sakai K; Yanagitani N; Ariyasu R; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Nishikawa S; Uchibori K; Horiike A; Nishio K; Nishio M
Cancer Sci; 2019 Oct; 110(10):3350-3357. PubMed ID: 31361375
[TBL] [Abstract][Full Text] [Related]
40. Compared to plasma, bronchial washing fluid shows higher diagnostic yields for detecting EGFR-TKI sensitizing mutations by ddPCR in lung cancer.
Lee SH; Kim EY; Kim T; Chang YS
Respir Res; 2020 Jun; 21(1):142. PubMed ID: 32517757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
